<p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href...

<p xmlns="http://www.w3.org/1999/xhtml">
<a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.neogenomics.com%2F&amp;esheet=54560075&amp;newsitemid=20260625576063&amp;lan=en-US&amp;anchor=NeoGenomics%2C+Inc.&amp;index=1&amp;md5=e8339a5dbb931f9878f69847e01231b1" shape="rect"><b xmlns="http://www.w3.org/1999/xhtml">NeoGenomics, Inc.</b></a><b xmlns="http://www.w3.org/1999/xhtml"> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NEO">NEO</a>)</b>, a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Ms. Starrett brings over 25 years of commercial, product, and operations experience at data and technology companies, and a deep understanding of AI and data insights in cancer care and research. She spent the last ten years, from 2016 to 2026, at Flatiron Health, serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from April 2021 to September 2025. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory firm, working with clients on strategic topics at the intersection of healthcare delivery, drug development, data, and AI.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"We are very excited to welcome Carolyn to the NeoGenomics board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Carolyn’s experience using real-world data and analytics to help accelerate improvements in cancer care and treatment will serve us well as we continue to expand our portfolio and impact for cancer patients. I look forward to her insights and guidance."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Ms. Starrett served as a Board Director at Foundation Medicine from 2021 to 2024. Prior to joining Flatiron, Ms. Starrett held several leadership roles at a predictive analytics company and led strategy and transformation efforts for healthcare and technology companies as a principal with Boston Consulting Group. She holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor&#39;s degree from Brown University.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"I am honored to join NeoGenomics’ board at an exciting time in the company’s evolution," said Ms. Starrett. "Neo’s growing portfolio of oncology diagnostics – paired with the new possibilities and insights enabled by AI – creates a real opportunity to improve cancer care for patients, and I look forward to contributing to this next phase of innovation."

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About NeoGenomics</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward Looking Statements</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "potential" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the Company’s strategy, planned future operations and development plans and initiatives, as well as the timing, outcome and potential for its offerings to deliver higher sensitivity results with faster turnaround times compared to currently available assays, and the potential impact on clinical treatment and patient prognosis. Applicable risks and uncertainties include, among others, the Company’s ability to successfully complete development of and to offer new types of tests, to execute on its strategic priorities and to otherwise implement its business plan, and the risks identified under the heading &#34;Risk Factors&#34; contained in the Company&#39;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company&#39;s other filings with the Securities and Exchange Commission.

</p><p xmlns="http://www.w3.org/1999/xhtml">
We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=54560075&amp;newsitemid=20260625576063&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=e11fa456ef9066de44ff400afe6c967f" shape="rect">www.sec.gov</a> for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260625576063r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260625576063/en/" rel="nofollow">https://www.businesswire.com/news/home/20260625576063/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Media Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Andrea Sampson
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:asampson@sampsonprgroup.com" shape="rect">asampson@sampsonprgroup.com 
</a><br xmlns="http://www.w3.org/1999/xhtml"></br>
<br xmlns="http://www.w3.org/1999/xhtml"></br><b xmlns="http://www.w3.org/1999/xhtml">Investor Contact 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:InvestorRelations@neogenomics.com" shape="rect">InvestorRelations@neogenomics.com</a>

</p>

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

NeoGenomics appoints Carolyn Starrett to board, signaling AI-focused data strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p xmlns=&quot;http://www.w3.org/1999/xhtml&quot;&gt;
&lt;a xmlns=&quot;http://www.w3.org/1999/xhtml&quot; rel=&quot;nofollow&quot; href...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>NeoGenomics appointed Carolyn Starrett to its board, adding a veteran leader in data-driven healthcare and AI. Her leadership at Flatiron Health and prior Foundation Medicine board role point to a strengthened strategy around real-world data and AI in oncology diagnostics. The move signals a governance shift aimed at expanding NeoGenomics&#039; test portfolio and improving outcomes through analytics-driven insights, with potential long-term earnings impact.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>NeoGenomics appoints Carolyn Starrett to its board. Brings 25+ years in AI and cancer data.</li><li>Starrett led Flatiron Health as CEO (2021-2025). Deep experience in real-world data.</li><li>Board appointment signals focus on AI-enabled diagnostics at NeoGenomics.</li><li>Starrett also served on Foundation Medicine board (2021-2024).</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>NeoGenomics, Inc. (NEO)</strong>: Board appointment signals governance shift toward data/AI-driven strategy.</li><li><strong>Flatiron Health (N/A)</strong>: Former CEO; indicates strong AI/data leadership contributing to NeoGenomics&#039; strategy.</li><li><strong>Foundation Medicine (N/A)</strong>: Former Board Director; ties to oncology diagnostics ecosystem.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article covers a leadership and governance move that could influence NeoGenomics&#039; strategic direction in AI-enhanced diagnostics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Board addition signals potential AI-driven expansion of NeoGenomics’ diagnostics portfolio.</li><li>Positive sentiment could attract partnerships and strategic collaborations.</li><li>Near-term earnings impact is uncertain; focus on AI-driven value creation.</li><li>Event may gradually improve multiple expansion as AI capabilities scale.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: June 25, 2026.</li><li>Carolyn Starrett appointed to NeoGenomics Board of Directors.</li><li>Starrett previously CEO/Board Director at Flatiron Health (Apr 2021–Sep 2025).</li><li>Board role at Foundation Medicine (2021–2024).</li><li>Background: 25+ years in commercial, product, operations, and AI/data.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bullish over 6–12 months as AI/data initiatives may expand NeoGenomics’ addressable market.</p>
  </section>
</section>


<article>
  <section>
    <h2>NeoGenomics Appoints Carolyn Starrett to its Board of Directors</h2>
    <p>NeoGenomics, Inc. (NASDAQ: <strong>NEO</strong>), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Carolyn Starrett to its Board of Directors. <strong>Ms. Starrett</strong> brings over <strong>25</strong> years of commercial, product, and operations experience at data and technology companies, and a deep understanding of AI and data insights in cancer care and research.</p>
  </section>

  <section>
    <h2>Executive Background: Carolyn Starrett’s Experience</h2>
    <h3>Career Highlights</h3>
    <p>She spent the last <strong>ten years</strong>, from <strong>2016</strong> to <strong>2026</strong>, at Flatiron Health, serving in a variety of executive roles and ultimately leading the company as CEO and Board Director from <strong>April 2021</strong> to <strong>September 2025</strong>. She is currently the President of Starrett Advisory, an independent consulting and strategic advisory firm, working with clients on strategic topics at the intersection of healthcare delivery, drug development, data, and AI.</p>
  </section>

  <section>
    <h2>Leadership Commentary on the Appointment</h2>
    <p>"We are very excited to welcome Carolyn to the NeoGenomics board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Carolyn’s experience using real-world data and analytics to help accelerate improvements in cancer care and treatment will serve us well as we continue to expand our portfolio and impact for cancer patients. I look forward to her insights and guidance."</p>
  </section>

  <section>
    <h2>Additional Board Experience and Education</h2>
    <p>Ms. Starrett served as a Board Director at Foundation Medicine from 2021 to 2024. Prior to joining Flatiron, Ms. Starrett held several leadership roles at a predictive analytics company and led strategy and transformation efforts for healthcare and technology companies as a principal with Boston Consulting Group. She holds an MBA from the Kellogg School of Management at Northwestern University and a bachelor’s degree from Brown University.</p>
  </section>

  <section>
    <h2>Leadership Perspective: Starrett on NeoGenomics’ Next Phase</h2>
    <p>"I am honored to join NeoGenomics’ board at an exciting time in the company’s evolution," said Ms. Starrett. "Neo’s growing portfolio of oncology diagnostics – paired with the new possibilities and insights enabled by AI – creates a real opportunity to improve cancer care for patients, and I look forward to contributing to this next phase of innovation."</p>
  </section>

  <section>
    <h2>About NeoGenomics</h2>
    <p><strong>NeoGenomics, Inc.</strong> is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to deliver timely, actionable insights that guide personalized care decisions. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, England.</p>
  </section>

  <section>
    <h2>Forward-Looking Statements</h2>
    <p>This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "potential" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the Company’s strategy, planned future operations and development plans and initiatives, as well as the timing, outcome and potential for its offerings to deliver higher sensitivity results with faster turnaround times compared to currently available assays, and the potential impact on clinical treatment and patient prognosis. Applicable risks and uncertainties include, among others, the Company’s ability to successfully complete development of and to offer new types of tests, to execute on its strategic priorities and to otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company&#34;s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company&#34;s other filings with the Securities and Exchange Commission.</p>
  </section>

  <section>
    <h2>Disclaimer and SEC Filings</h2>
    <p>We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p>
  </section>

  <section>
    <h2>Key Facts at a Glance</h2>
    <ul>
      <li><strong>Appointment</strong>: Carolyn Starrett named to NeoGenomics' Board of Directors</li>
      <li><strong>Experience</strong>: Over <strong>25</strong> years in commercial, product, and operations roles at data and technology companies</li>
      <li><strong>Flatiron Health tenure</strong>: Spent <strong>ten years</strong> at Flatiron Health, from <strong>2016</strong> to <strong>2026</strong>, leading as CEO and Board Director from <strong>April 2021</strong> to <strong>September 2025</strong></li>
      <li><strong>Current role</strong>: President of Starrett Advisory</li>
      <li><strong>Past board roles</strong>: Board Director at Foundation Medicine (2021–2024)</li>
      <li><strong>Education</strong>: MBA from Kellogg School of Management; Brown University</li>
      <li><strong>Stock ticker</strong>: NEO</li>
    </ul>
  </section>

  <section>
    <h2>Contacts</h2>
    <p><strong>Media Contact</strong><br>Andrea Sampson<br><a href="mailto:asampson@sampsonprgroup.com">asampson@sampsonprgroup.com</a></p>
    <p><strong>Investor Contact</strong><br><a href="mailto:InvestorRelations@neogenomics.com">InvestorRelations@neogenomics.com</a></p>
  </section>
</article>

NeoGenomics appointed Carolyn Starrett to its board, adding a veteran leader in data-driven healthcare and AI. Her leadership at Flatiron Health and prior Foundation Medicine board role point to a strengthened strategy around real-world data and AI in oncology diagnostics. The move signals a governance shift aimed at expanding NeoGenomics' test portfolio and improving outcomes through analytics-driven insights, with potential long-term earnings impact.

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News